InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Proposed issue of Securities - MXC 20 Jul 2020 9:42AM $0.024 $0.420 risen by 1,650%
$18 MGC Pharma to acquire 100% of Medicinal Cannabis Clinic 20 Jul 2020 9:31AM $0.024 $0.420 risen by 1,650%
$18 Change of Director's Interest Notice - Appendix 3Y x 2 15 Jul 2020 2:15PM $0.024 $0.420 risen by 1,650%
$18 MXC Cannabis Research Permit Granted for RMIT Programs 14 Jul 2020 8:41AM $0.023 $0.420 risen by 1,726.09%
$18 Appendix 2A 10 Jul 2020 2:32PM $0.025 $0.420 risen by 1,580%
$18 MGC Pharma awarded Import Licence by Office of Drug Control 8 Jul 2020 9:08AM $0.022 $0.420 risen by 1,809.09%
$18 Results of General Meeting 2 Jul 2020 6:16PM $0.021 $0.420 risen by 1,900%
$18 COVID-19 Clinical Trial Site Expansion into India 2 Jul 2020 10:22AM $0.020 $0.420 risen by 2,000%
$18 MGC Pharma GM Webinar 26 Jun 2020 11:25AM $0.022 $0.420 risen by 1,853.49%
$18 INVESTOR PRESENTATION 24 Jun 2020 9:14AM $0.022 $0.420 risen by 1,809.09%
$18 MXC Awarded 3-year EU GMP Manufacturing Licence 23 Jun 2020 9:50AM $0.022 $0.420 risen by 1,809.09%
$18 Unmarketable Parcel Share Sale Facility 22 Jun 2020 11:44AM $0.022 $0.420 risen by 1,809.09%
$18 Sale of MGC Nutra to US CBD and Hemp Wellness Company 18 Jun 2020 9:26AM $0.023 $0.420 risen by 1,726.09%
$18 Binding Term Sheet for distribution of CannEpil in Israel 15 Jun 2020 9:27AM $0.024 $0.420 risen by 1,650%
$18 3,250 Prescriptions Milestone Surpassed 2 Jun 2020 9:37AM $0.023 $0.420 risen by 1,726.09%
$18 Letter to Shareholders - Upcoming General Meeting 29 May 2020 1:28PM $0.024 $0.420 risen by 1,650%
$18 Notice of General Meeting/Proxy Form 29 May 2020 1:23PM $0.024 $0.420 risen by 1,650%
$18 Ethics Committee Approval for CannEpil Phase IIb Trial 26 May 2020 9:20AM $0.025 $0.420 risen by 1,580%
$18 Reinstatement to Official Quotation 13 May 2020 9:33AM $0.026 $0.420 risen by 1,515.38%
$18 Binding Term Sheet Signed for Distribution of ArtemiC 13 May 2020 9:32AM $0.026 $0.420 risen by 1,515.38%
$18 Extension of Voluntary Suspension 12 May 2020 8:54AM $0.026 $0.420 risen by 1,515.38%
$18 Issue of Options - Appendix 2A 11 May 2020 1:03PM $0.026 $0.420 risen by 1,515.38%
$18 Voluntary Suspension 11 May 2020 9:28AM $0.026 $0.420 risen by 1,515.38%
$18 Trading Halt 7 May 2020 10:16AM $0.026 $0.420 risen by 1,515.38%
$18 Pause in Trading 7 May 2020 9:56AM $0.026 $0.420 risen by 1,515.38%

426 - 450 of 818 results

Page 18 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.